Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: US79400X4043 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Modalis Therapeutics Corporation Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.	Japan	4883
Model Solution Co., Ltd. One-stop prototyping & low-volume production for IT, electronics, and medical hardware.	South Korea	417970
Modus Therapeutics Holding AB Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.	Sweden	MODTX
Moleculin Biotech, Inc. Developing therapies for hard-to-treat tumors (like AML) and viruses.	United States of America	MBRX
Molecure S.A. Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.	Poland	MOC
Moolec Science SA Uses Molecular Farming to grow animal proteins in plants for food, feed, and supplement industries.	United States of America	MLEC
MoonLake Immunotherapeutics Developing Nanobody therapies for inflammatory and immunologic diseases like psoriatic arthritis.	United States of America	MLTX
Mural Oncology plc Developing cytokine-based immunotherapies for difficult-to-treat cancers and solid tumors.	United States of America	MURA
Mural Oncology PLC Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.	Ireland	MURA
N2OFF, Inc. Sustainable agri-tech for food preservation, emissions reduction, and renewable energy.	United States of America	NITO